Azacyclic ethynyl derivatives
This invention relates to novel azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
1. An azacyclic ethynyl derivative of Formula II:
any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein
n is 0;
R represents hydrogen, alkyl or cycloalkyl;
L is absent; and
X represents an aromatic mono- or polycyclic, carbocyclic group, which aromatic group is optionally substituted one or more times with alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, cycloalkoxy, halogen, CF 3 , OCF 3 , cyano, amino, nitro, aryl, aryloxy and/or aralkyl.
2. The azacyclic ethynyl derivative of claim 1 , wherein R represents hydrogen or alkyl; and X represents a phenyl group, which phenyl is optionally substituted one or two times with alkyl, cycloalkyl, alkoxy, cycloalkoxy, halogen, CF 3 , OCF 3 , cyano, amino, or nitro.
3. The azacyclic ethynyl derivative of claim 2 , which is
(±)-8-Methyl-3-phenyletynyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-8,8-Dimethyl-3-phenyletynyl-8-azabicyclo[3.2.1]oct-2-ene iodide;
(±)-8-H-3-Phenyletynyl-8-azabicyclo[3.2.1]oct-2-ene;
(±)-8-Methyl-3-(2,4-difluorophenyletynyl)-8-azabicyclo[3.2.1]oct-2-ene;
(±)-8-Methyl-3-(1-cyclohexenyletynyl)-8-azabicyclo[3.2.1]oct-2-ene;
(±)-8-Methyl-3-(4-toluyletynyl)-8-azabicyclo[3.2.1]oct-2-ene;
(±)-8-Methyl-3-(4-methoxyphenyletynyl)-8-azabicyclo[3.2.1]oct-2-ene; or
or an enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a therapeutically effective amount of an azacyclic ethynyl derivative of claim 1 , or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.